Nav: Home

Scientists use machine learning to predict major clinical forms of drug cardiotoxicity

June 09, 2020

June 9, 2020 - We announce the publication of a new research paper titled 'Dual transcriptomic and molecular machine learning predicts all major clinical forms of drug cardiotoxicity' in . The study was conducted in a collaboration between the Computational Cardiovascular Science Group of the
'Drug-induced adverse effects on the heart are a very important problem, as highlighted recently in the news regarding COVID-19 treatments. In this study, we are very excited to show how our machine learning algorithm can identify drugs that can cause 6 potential forms of cardiac adverse outcomes from gene expression data', said Professor Blanca Rodriguez.

'Thanks to the increasing power of computers and algorithms to learn, this work represents an exemplar of how AI will revolutionise the future of drug development and safety evaluation in the pharma industry. It extends previous efforts in the field to predict not only the likelihood of a drug to induce lethal arrhythmias, but all the main cardiac adverse events associated with drug action. It also establishes the need for stringent testing criteria for the effective application of AI to this critical domain of the life sciences', said Professor Alfonso Bueno-Orovio.

Computational methods can increase the productivity of drug discovery pipelines, through overcoming challenges such as cardiotoxicity identification. In this paper, researchers demonstrated the simultaneous prediction of cardiotoxic relationships for six drug-induced cardiotoxicity types using a machine learning approach on a large collected and curated dataset of transcriptional and molecular profiles. The algorithm generality is demonstrated through validation in an independent drug dataset, in addition to cross-validation.

Alex Zhavoronkov, founder and CEO of Insilico Medicine comments, 'Drug-induced cardiotoxicity is one of the reasons for late-stage clinical trial failures. We see the Rodriguez group at Oxford as the world's main source of accurate cardiotoxicity predictors. The results of their work are adopted by the FDA, and many pharmaceutical companies. We are very happy to collaborate on AI-powered multi-omics cardiotoxicity prediction engines, and have one of our top AI scientists, Polina Mamoshina, defend her doctorate under one of the biggest names in computational biomedicine'.

Polina Mamoshina, is now Senior Research Scientist at Insilico Medicine. She comments, 'In silico or computational models have made great progress in past years. And one of their great features is that they can be humanized and so have increased chances for translation into drug discovery and development pipelines. The scope of this work was to predict drug adverse reactions that were shown in humans. We believe that this work can be extended to side effects manifested in other organs and tissues and that pipeline that we proposed provides a valuable benchmark for future studies'.
-end-
Read the original research paper here:
https://ora.ox.ac.uk/objects/uuid:2b143ed7-9630-4802-b707-9fb226203384?fbclid=IwAR2bzf3SdQVSzGge3PeB4DBkzSqU55wK4tDRcaTNmvMoNjg5izuNd_dkiFU

Media Contact

For further information, images or interviews, please contact: ai@insilico.com

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Since its inception, Insilico Medicine raised over $52 million, published over 70 peer-reviewed papers, applied for over 20 patents, and received multiple industry awards. Website http://insilico.com/

InSilico Medicine

Related Announce Articles:

Female directors are quicker to recall dangerous medical products, study shows
Some 4,500 Food and Drug Administration-approved drugs and devices are pulled from shelves annually -- decisions greatly influenced by the presence of women on a firm's board, according to new research from the University of Notre Dame.
Chewing gum use in the perioperative period
Many anesthesiologists forbid patients from chewing gum in the immediate hours before surgery for fear that it would increase the risk that the patient's stomach contents might end up dumped (aspirated) into the patient's lungs, with potentially deadly consequences (aspiration pneumonitis).
NSF and Popular Science announce winners of 15th annual 'Vizzies'
'Vizzies' competition recognizes the best photographs, videos, illustrations, interactive apps, and posters and graphics produced by academic researchers, artists or hobbyists.
Four year agreement to supply Silicon Carbide micro-fiber
Haydale Graphene Industries plc the UK listed global nanomaterials group, is pleased to announce that its subsidiary, Advanced Composite Materials LLC, has entered into a four-year agreement to supply Silicon Carbide micro-fiber to a global industrial manufacturer of tooling and wear-resistant solutions.
BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells
BioCanRx, and its partners, today announced funding for 16 collaborative research projects in novel therapies to cure cancer including research aimed at developing clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities in Canada.
QMUL and BH announce major new initiative in the Life Sciences
Queen Mary University of London (QMUL) and Barts Health NHS Trust (BH) announce plans for a major new center for Life Sciences in Whitechapel, home to the Royal London Hospital and a campus of QMUL's Barts and The London School of Medicine and Dentistry.
WDS DSA announce unified requirements for Core Trustworthy Data Repositories certification
The ICSU World Data System and the Data Seal of Approval Board are pleased to announce the availability of their unified Requirements for Core Trustworthy Data Repository certification.
CDISC, C-Path, and TransCelerate announce TA standard for kidney transplant
The Coalition for Accelerating Standards and Therapies (CFAST), with TransCelerate BioPharma, Inc., announce the availability of a new Clinical Data Interchange Standards Consortium (CDISC) Therapeutic Area Standard for Kidney Transplantation -- the first CDISC standard to address a therapeutic area in the field of solid organ transplant.
AHA and China Social Assistance Foundation announce the establishment of the first AHA international training center in China with focus on bystander response to cardiac arrest
A remarkable milestone for future cooperation in the advancement of CPR training to reduce cardiovascular disease mortality.
AHA, Verily Life Sciences, AstraZeneca announce winner of $75M One Brave Idea research award
The American Heart Association (AHA), Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, and AstraZeneca, today announced that the One Brave Idea™; research award.

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.